Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "Genitourinary" returned 11 results:


An open-label multicenter study of Sipuleucel-T in metastatic castrate resistant prostate cancer patients previously treated with Sipuleucel-T on Dendreon Study P-11
Principal Investigator(s): Simon J. Hall

Multi-center Phase 2 Trial of Single-agent Amrubicin as second-line therapy in patients with Advanced/Metastatic Refractory Urothelial Carcinoma
Principal Investigator(s): Matthew Galksy

Phase I/II Study of BNC105P in Combination with Everolimus or Following Everolimus for Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors. Hoosier Oncology Group GU09-145 (Kidney)
Principal Investigator(s): Matthew Galsky

A Randomized, Phase 2, Open Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma
Principal Investigator(s): Simon J. Hall

Phase II Trial of Everolimus or Everolimus plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma
Principal Investigator(s): Matthew Galsky

Predicting Response to Platinum Chemotherapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Using a Genomic Signature for "BRCAness," A Phase II Prospective Open Label Clinical Trial of Second Line Satraplatin in Men with mCRPC
Principal Investigator(s): William Oh

Multi-Center Phase IB/II Trial of Gemcitabine, Cisplatin, Plus Lenalidomide as First-Line Therapy for Patients with Metastatic Urothelial Carcinoma
Principal Investigator(s): Matthew Galsky

A Phase I Neoadjuvant Study of In-Situ REIC/Dkk-3 Gene Therapy Followed by Prostatectomy in Patients with High Risk of Localized Prostate Cancer (MTG-REIC-PC001)
Principal Investigator(s): Simon J. Hall

An International Phase 3, Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
Principal Investigator(s): Michael A. Palese

A Pilot Study of Abiraterone Acetate in African American/Black Patients with Castration Resistant Prostate Cancer
Principal Investigator(s): Matthew Galsky

A Randomized, Open-Label, Phase 2 Trial Of Sipuleucel-T With Concurrent Versus Sequential Administration Of Abiraterone Acetate Plus Prednisone In Men With Metastatic Castrate Resistant Prostate Cancer
Principal Investigator(s): Simon J. Hall